L&G PHARMA BREAKTHROUGH UCITS ETF

A sub-fund of Legal & General UCITS ETF Plc, an umbrella investment company with variable capital and segregated liability between its Funds.

This Supplement contains information relating to the L&G Pharma Breakthrough UCITS ETF (the "Fund") which is a separate Fund of Legal & General UCITS ETF Plc (the "Company"). This Supplement forms part of and should be read in the context of, and together with, the Prospectus dated 18 September 2026. If you are in any doubt about the action to be taken or the contents of this Supplement, please consult your stockbroker or other financial adviser. Potential investors should consider the risk factors set out in the Prospectus and in this Supplement before investing in this Fund. An investment in the Fund involves certain risks and may only be suitable for persons who are able to assume the risk of losing their entire investment.

FUND DETAILS

Base Currency	USD.
Investment Approach	Index Tracking – Physical Replication.
Eligible Assets	Equity Securities; Depositary Receipts; FDIs namely, Total Return Swaps, forward currency contracts (including non-deliverable forwards) and Equity Futures; Money Market Funds.
Securities Financing Transactions	Securities Lending: Maximum 45%, Expected 0-20%. Repurchase, Reverse Repurchase and TRS Transactions: Maximum 100%, Expected 0%.
SFDR	Article 9.
Summary of the Sustainable Objective	The sustainable investment objective of the Fund is to provide exposure to bio-technology companies that are actively engaged in the research, development and/or manufacturing of orphan drugs. Further information on the sustainable objective of the Fund can be found in the Annex.
Index	Solactive Pharma Breakthrough Value Index Net Total Return.
Index Rebalancing	Semi-annually in March and September.
Index Characteristics	The Index is a Net Total Return Index.
Additional Index Details	Further information on the Index methodology, constituents and weightings can be found here.
TER	Unhedged Classes: 0.49%, Hedged Classes: 0.54%.
Minimum Subscription / Redemption Amount	50,000 Shares.
Initial Offer Price	Approximately USD 10, expressed in the class currency of the relevant class.
Initial Offer Period	Unlaunched Shares in each class will be available at the Initial Offer Price from 9 am UK time on 21 September 2026 to 4:00 pm on 19 March 2027 or such earlier or later date as the Directors may determine and notify to the Central Bank.
Transaction Charges	In respect of each subscription or redemption of Shares, the Manager (or its delegate) may apply Duties and Charges or an Anti-Dilution Levy either as a fixed amount or on an actual cost basis. Any fixed charge shall not exceed 5% of the Net Asset Value of the Shares subscribed for or redeemed.

Capitalised expressions used and not defined in this Supplement shall bear the meanings as set out in the Prospectus.

INVESTMENT OBJECTIVE

The investment objective of the Fund is to provide exposure to bio-technology companies that are actively engaged in the research, development and/or manufacturing of orphan drugs.

INVESTMENT POLICY

In order to achieve this investment objective, the Fund will seek to track the performance of the Index, before the deduction of the TER and other Fund expenses, as further described under "*Fees and Expenses*" in the Prospectus. It will do so by investing, as far as possible and practicable, in the Index Securities, in the same proportions as their weightings in the Index.

Accordingly, the Fund may have exposure to or invest directly up to 20% of its Net Asset Value in shares issued by the same body, which limit may be raised to 35% for a single issuer in exceptional market conditions, including (but not limited to) circumstances in which such issuer occupies a dominant market position.

The Index is designed to provide exposure to publicly traded bio-technology companies that are actively engaged in the research, development and/or manufacturing of orphan drugs. An "orphan drug" is a pharmaceutical product that has been developed specifically to treat rare diseases or disorders. The Index will exclude companies which are constituents of the "ESG Exclusions Enhanced Index", as detailed in the Annex. Such exclusions and the definition of "involvement" are determined by reference to the "ESG Exclusions Enhanced Index", published by Solactive AG which is available here.

The Index selects stocks of companies that meet certain size and liquidity requirements using a two-fold approach that is primarily based on the trend in the valuation of a company's orphan drug portfolio and its net assets.

Companies whose securities are eligible for inclusion in the Index Universe are determined by Solactive AG in accordance with the process described in the Index methodology.

PROFILE OF A TYPICAL INVESTOR

It is expected that investors in the Fund will be informed investors who: (i) have taken professional advice and who understand (and are able to bear) the risk of losing their investment; and (ii) can accept the levels of risks associated with investing in global equity markets, in particular in bio-technology companies.

RISK FACTORS

Investors are referred to "*Risk Factors*" and Schedule II of the Prospectus and should consider all relevant risk factors prior to investing in the Fund. Investors should consider, in particular those relating to Shares, Index Tracking-Related Risks, Sustainability Risks, Equity Risk and Pharmaceutical Companies Risk and Micro, Small and Mid-Capitalisation Companies Risk.

INDEX DISCLAIMER

The Fund is not sponsored, promoted, sold or supported by the Solactive AG. Nor does Solactive AG offer any express or implicit guarantee or assurance either with regard to the results of using the Index and/or Index trade mark or the Index price, at any time or in any other respect.

The Index is calculated and published by Solactive AG. Solactive AG uses its best efforts to ensure that the Index is calculated correctly. Irrespective of its obligations towards the Company, Solactive AG has no obligation to point out errors in the Index to third parties including, but not limited to, investors and/or financial intermediaries of the Fund. Solactive AG does not guarantee the accuracy and/or the completeness of the Index or any related data, and shall not have any liability for any errors, omissions or interruptions therein.

Neither publication of the Index by Solactive AG, nor the licensing of the Index or Index trade mark, for the purpose of use in connection with the Fund, constitutes a recommendation by Solactive AG to invest capital in said Fund nor does it, in any way, represent an assurance or opinion of Solactive AG with regard to any investment in this Fund. In no event shall Solactive AG have any liability for any lost profits or indirect, punitive, special or consequential damages or losses, even if notified of the possibility thereof.

ANNEX III

Template pre-contractual disclosure for the financial products referred to in Article 9, paragraphs 1 to 4a, of Regulation (EU) 2019/2088 and Article 5, first paragraph, of Regulation (EU) 2020/852

Sustainable investment means an investment in an economic activity that contributes to an environmental or social objective, provided that the investment does not significantly harm any environmental or social objective and that the investee companies follow good governance practices.	**Product name:**	: L&G Pharma Breakthrough UCITS ETF	**Legal entity identifier:**	213800GUQHPUIT7GGC50

Sustainable investment objective

Does this financial product have a sustainable investment objective?

X Yes	**☐ No**
☐ It will make a minimum of **sustainable investments with an environmental objective:** __%	☐ It **promotes Environmental/Social (E/S) characteristics** and while it does not have as its objective a sustainable investment, it will have a minimum proportion of XX.XX% of sustainable investments
☐ in economic activities that qualify as environmentally sustainable under the EU Taxonomy	☐ with an environmental objective in economic activities that qualify as environmentally sustainable under the EU Taxonomy
☐ in economic activities that do not qualify as environmentally sustainable under the EU Taxonomy	☐ with an environmental objective in economic activities that do not qualify as environmentally sustainable under the EU Taxonomy
	☐ with a social objective
X It will make a minimum of **sustainable investments with a social objective**: 90 %	☐ It promotes E/S characteristics, but **will not make any sustainable investments**

The **EU Taxonomy** is a classification system laid down in Regulation (EU) 2020/852, establishing a list of **environmentally sustainable economic activities**. That Regulation does not lay down a list of socially sustainable economic activities. Sustainable investments with an environmental objective might be aligned with the Taxonomy or not.

What is the sustainable investment objective of this financial product?

The sustainable investment objective of the Fund is to provide exposure to bio-technology companies that are actively engaged in the research, development and/or manufacturing of orphan drugs. The Fund seeks to achieve its investment objective by tracking the performance of the Solactive Pharma Breakthrough Value Index Net Total Return (the "Index").

The Index is a reference benchmark that has been designated for the purpose of attaining the sustainable investment objective of the Fund.


Sustainability indicators measure how the sustainable objectives of this financial product are attained.

What sustainability indicators are used to measure the attainment of the sustainable investment objective of this financial product?

1. The proportion of the relevant comparator index excluded through the application of the exclusionary criteria set out below;

	2. Confirmation of exposure to the sustainable theme set out below.
Principal adverse impacts are the most significant negative impacts of investment decisions on sustainability factors relating to environmental, social and employee matters, respect for human rights, anti-corruption and anti-bribery matters.	***How do sustainable investments not cause significant harm to any environmental or social sustainable investment objective?***
	The Fund applies the following exclusions through tracking the Index in accordance with the Index methodology: • companies which are non-compliant with the UN Global Compact, • companies that are associated with a controversy (i.e. companies that have been involved in events that have a severe impact on the environment and society, posing serious business risks to the company), • companies that are involved in the production or retail of tobacco, or are a related product/service, • companies that are involved in military contracting weapons or related products, • companies that are involved in the retail or distribution of small arms to civilians (assault and non-assault weapons) and military/law enforcement customers, as well as key components of small arms, • companies that are involved in thermal coal extraction, power generation or increase the power generation capacity of coal • companies that are involved in the generation, production or increase the capacity of conventional oil and gas, or supporting products/services, • companies that are involved in oil sands extraction, arctic oil & gas exploration/extraction, shale energy extraction or increase the capacity of unconventional oil & gas, • companies that are involved in the production, distribution, supporting products or capacity increase of nuclear power, • companies that are involved in the production, retail or related services/products of alcohol, • companies that are involved in the operations, specialized equipment or supporting products/services of gambling, and • companies that are involved in the production or distribution of adult entertainment. Through the application of the above listed exclusions it is ensured that the investments held by the Fund do not significantly harm any environmental or social objectives.
	How have the indicators for adverse impacts on sustainability factors been taken into account?
	The Investment Manager assessed the Index against all sustainability indicators outlined in Table 1 of Annex I of Commission Delegated (EU) 2022/1288 (the "SFDR Level 2 Measures") and a majority of them are taken into account directly or indirectly by application of the above-listed exclusions. A direct approach occurs where an exclusionary screen incorporates, in its methodology, the metric defined in Table 1 of Annex I of the SFDR Level 2 Measures relating to the relevant sustainability indicator. The indirect approach will incorporate different metrics that are not defined in Table 1 of Annex I of the SFDR Level 2 Measures but associated with the sustainability indicators, such as norms-based or controversy screens to exclude issuers involved in violations. It should be noted that a small subset of sustainability indicators is not directly or indirectly mapped to the above-listed exclusions following consideration of their appropriateness to the Fund's investment strategy. The rationale for this may include inadequate data quality or coverage, or limited relevance to the Fund's eligible investment universe.
	How are the sustainable investments aligned with the OECD Guidelines for Multinational Enterprises and the UN Guiding Principles on Business and Human Rights
	The Fund's sustainable investments are aligned with the OECD Guidelines for Multinational Enterprises and the UN Guiding Principles on Business and Human Rights through the application of the sustainability-related investment strategy used to attain the sustainable investment objective. In

	particular, the Index is designed to comply with the principles of the United Nation Global Compact and excludes companies that are associated with a controversy (i.e. companies that have been involved in events that have a severe impact on the environment and society, posing serious business risks to the company). Accordingly, the Fund's investments aim to indirectly follow the UN Guiding Principles on Business and Human Rights, as well as the OECD Guidelines for Multinational Enterprises.
	**Does this financial product consider principal adverse impacts on sustainability factors?**
	▪ Yes ▪ No
	Yes
	The Fund considers principal adverse impacts on sustainability factors. The Investment Manager takes the adverse sustainability indicators listed in Table 1 of Annex I of the SFDR Level 2 Measures into account, except for a small subset of indicators as explained above. The Fund considers principal adverse impacts, that are identified using the above-mentioned indicators, by tracking the Index that employs the sustainability-related investment strategy outlined below in line with its methodology. For example, the Fund uses the 'Exposure to companies active in the fossil fuel sector' indicator (indicator 4 of Table 1 of Annex I of SFDR) to identify principal adverse impacts relating to greenhouse gas emissions and then considers and takes actions in relation to principal adverse impacts identified through tracking the Index that excludes companies that are involved in (i) thermal coal extraction, power generation or supporting products/services, (ii) the generation, production of conventional oil and gas, or supporting products/services, or (iii) in oil sands extraction, arctic oil & gas exploration/extraction or shale energy extraction. Further information on how the Manager and the Investment Manager consider principal adverse impacts on an entity level can be found in the Sustainability Policy which is available on LGIM's website. Reporting on principal adverse impacts on sustainability factors will be made available in the annual report of the Fund.
	**What investment strategy does this financial product follow?**
	The Fund follows the following sustainability-related investment strategy by tracking the Index: **Sustainable Theme:** The Index is comprised of bio-technology companies that are actively engaged in the research, development and/or manufacturing of orphan drugs that treat rare diseases. Companies eligible for inclusion in the Index universe shall be determined based on industry classification data provided by an independent third-party provider of consensus forecasts of leading industry analysts and analysis of the pharmaceutical and biotechnology healthcare sectors. In order to be eligible for inclusion in the Index a company must have a minimum of two marketed orphan drugs and must derive a proportion of revenue from orphan drugs which is within the top two quartiles of relevant orphan drugs companies, as determined by an independent third-party provider. **ESG Enhanced Exclusions**: the Index excludes companies which (i) are non-compliant with the UN Global Compact, (ii) are associated with a controversy (i.e. companies that have been involved in events that have a severe impact on the environment and society, posing serious business risks to the company), (iii) are involved in the production or retail of tobacco, or are a related product/service, (iv) are involved in military contracting weapons or related products, (v) are directly involved or indirectly involved through corporate ownership, in controversial weapons, (vi) are involved in the retail or distribution of small arms to civilians (assault and non-assault weapons) and military/law enforcement

	customers, as well as key components of small arms, (vii) are involved in thermal coal extraction, power generation or increase the power generation capacity of coal (viii) are involved in the generation, production or increase the capacity of conventional oil and gas, or supporting products/services, (ix) are involved in oil sands extraction, arctic oil & gas exploration/extraction, shale energy extraction or increase the capacity of unconventional oil & gas, (x) are involved in the production, distribution, supporting products or capacity increase of nuclear power, (xi) are involved in the production, retail or related services/products of alcohol, (xii) are involved in the operations, specialized equipment or supporting products/services of gambling, and (xiii) are involved in the production or distribution of adult entertainment. Such exclusions and the definition of "involvement" are determined by the Index provider and disclosed in further detail on the Solactive AG website.
The investment strategy guides investment decisions based on factors such as investment objectives and risk tolerance.	***What are the binding elements of the investment strategy used to select the investments to attain the sustainable investment objective?***
Good governance practices include sound management structures, employee relations, remuneration of staff and tax	The Fund aims to track the Index in accordance with its investment policy. As a result, the investment strategy set out above is binding on the investment decision-making process of the Fund. ***What is the policy to assess good governance practices of the investee companies?*** The Investment Manager ensures that the investee companies in which the Fund invests follow good governance practices by tracking an index that excludes companies that (i) fail to meet globally accepted norms and standards relating to governance matters (such as the UN Global Compact principles), or (ii) are involved in incidents with negative governance implications. As part of its due diligence the Investment Manager assessed the Index to ensure compliance with these requirements. In addition, the Investment Manager also integrates the principles of good governance practices into its stewardship and engagement approach by setting expectations with investee companies' management regarding good governance practices; actively engaging with the investee companies; utilising its voting rights; and supporting policymakers and legislators to ensure there is strong regulation and standards.
 **Asset allocation** describes the share of investments in specific assets.	**What is the asset allocation and the minimum share of sustainable investments?** The Fund will invest at least 90% of its portfolio in investments that qualify as sustainable (#1), all of which provide direct exposure to investee companies. The Fund will invest at least 0% of its portfolio in environmentally sustainable investments and at least 90% of its portfolio in socially sustainable investments. The actual level of environmentally and socially sustainable investments held by the Fund will always equate to at least the minimum proportion of sustainable investments of the portfolio outlined above. Some of the sustainable investments may be considered to contribute to both environmental and social objectives. The remaining portion of investments are not used to meet the sustainable investment objective and will fall under #2 Not sustainable.
Taxonomy-aligned activities are expressed as a share of: -**turnover** reflecting the share of revenue from green activities of investee companies -**capital expenditure** (CapEx) showing the	

green investments made by investee companies, e.g. for a transition to a green economy.
-**operational expenditure** (OpEx) reflecting green operational activities of investee companies.

#1 Sustainable covers sustainable investments with environmental or social objectives.
#2 Not sustainable includes investments which do not qualify as sustainable investments.

How does the use of derivatives attain the sustainable investment objective?

The Fund does not make use of derivatives to attain the sustainable investment objective.

To what minimum extent are sustainable investments with an environmental objective aligned with the EU Taxonomy?

The Fund does not invest in sustainable investments with an environmental objective.

Does the financial product invest in fossil gas and/or nuclear energy related activities that comply with the EU Taxonomy[1]?


☐ Yes:

☐ In fossil gas ☐ In nuclear energy

X No

To comply with the EU Taxonomy, the criteria for **fossil gas** include limitations on emissions and switching to fully renewable power or low-carbon fuels by the end of 2035. For **nuclear energy**, the criteria include comprehensive safety and waste management rules.
Enabling activities directly enable other activities to make a substantial contribution to an environmental objective.
Transitional activities are activities for which low-carbon alternatives are not yet available and

The two graphs below show in green the minimum percentage of investments that are aligned with the EU Taxonomy. As there is no appropriate methodology to determine the Taxonomy-alignment of sovereign bonds*, the first graph shows the Taxonomy alignment in relation to all the investments of the financial product including sovereign bonds, while the second graph shows the Taxonomy alignment only in relation to the investments of the financial product other than sovereign bonds.



** For the purpose of these graphs, 'sovereign bonds' consist of all sovereign exposures*

[1] Fossil gas and/or nuclear related activities will only comply with the EU Taxonomy where they contribute to limiting climate change ("climate change mitigation") and do not significantly harm any EU Taxonomy objectives -see explanatory note in the left hand margin. The full criteria for fossil gas and nuclear energy economic activities that comply with the EU Taxonomy are laid down in Commission Delegated Regulation (EU) 2022/1214.

among others have greenhouse gas emission levels corresponding to the best performance.	
are environmentally sustainable investments that **do not take into account the criteria** for environmentally sustainable economic activities under the EU Taxonomy.	***What is the minimum share of investments in transitional and enabling activities?***
	The Fund does not invest a minimum share of investments in transitional and enabling activities within the meaning of the Taxonomy Regulation.
	 **What is the minimum share of sustainable investments with an environmental objective that are not aligned with the EU Taxonomy?**
	The Fund does not invest in sustainable investments with an environmental objective.
	 **What is the minimum share of sustainable investments with a social objective?**
	The minimum share of sustainable investments with a social objective is set at 90% of the Fund's portfolio.
	 **What investments are included under "#2 Not sustainable", what is their purpose and are there any minimum environmental or social safeguards?**
	Other holdings may include cash, depositary receipts, money market funds and derivatives. Such investments may be used for investment purposes and efficient portfolio management. Derivatives may also be used for currency hedging for any currency hedged share classes. Environmental or social safeguards applied by the Index are only applied to instruments that are used to attain exposure to an Index constituent. The Investment Manager considers ESG factors, including analysis from the relevant responsible investing methodologies as part of assessing the credit risk profile of its most significant counterparties. The Investment Manager has an internal control framework in place to consider and take appropriate action in the event that a significant counterparty fails to meet any minimum standards in respect of such ESG factors as defined by the Investment Manager
	**Is a specific index designated as a reference benchmark to meet the sustainable investment objective?**
Reference benchmarks are indexes to measure whether the financial product attains the sustainable investment objective.	Yes, the Index is designated as a reference benchmark.
	How does the reference benchmark take into account sustainability factors in a way that is continuously aligned with the sustainable investment objective?
	The Index is continuously aligned with the sustainable investment objective of the Fund by providing exposure to companies in accordance with the sustainability-related investment strategy described above. At each index rebalance, the selection criteria of the Index are applied to its constituents.
	How is the alignment of the investment strategy with the methodology of the index ensured on a continuous basis?
	The Fund invests, in a portfolio of securities that, as far as possible and practicable, consists of the component securities of the Index in similar proportions to their weightings in the Index.
	How does the designated index differ from a relevant broad market index**?**

	The Index is comprised of bio-technology companies that are actively engaged in the research, development and/or manufacturing of orphan drugs that treat rare diseases and therefore constitutes a smaller sub-set of a broad market index.
	Where can the methodology used for the calculation of the designated index be found?
	For further information in relation to the Index methodology please see: Solactive | Indices
	**Where can I find more product specific information online?** **More product-specific information can be found on the website:**
	L&G Pharma Breakthrough UCITS ETF - LGIM Fund Centre